Gbola Amusa

Moderna Analyst Breaks Down Biopharma's Coronavirus Vaccine Pricing
Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data
Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster
Adverum Biotech Shares Move Higher On Positive Wet AMD Gene Therapy Data
Biotech Stock On The Radar: Medicines Company, A Cardiovascular Pure Play With A Potential Blockbuster
6 Gene Therapy M&A Targets On The Radar
Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Gbola Amusa Recent News

Analyst: Solid Biosciences A Solid Buy On Sarepta's Progress
3 Possible Outcomes From The Clinical Hold On Crispr Therapeutics's Sickle Cell Candidate
Chardan's Top Pick For 2018: Gene Therapy Firm Uniqure
Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson
Analyst: AveXis M&A Could Support Interest In Regenxbio
Chardan: Why The Novartis-AveXis Acquisition Is Good News For The Gene Therapy Space
Pair Trade Closed: Chardan No Longer Advocates Owning vTv Therapeutics Over Axovant
Solid Biosciences Snags Bullish Initiation As It Develops Gene Therapy For Muscular Dystrophy
Analyst Lifts Catalyst Biosciences PT From $10 To $75 On Hemophilia B Product
After A Freefall In Axovant Shares, Chardan Upgrades
There Could Be 109% Upside In uniQure As Company Advances Gene Therapy Into Clinical Trials
Expect More Downside In Axovant Sciences
Sage Therapeutics Falls Hard After Brexanolone Drug Fails Phase III Testing
Medicines Company Gets FDA Approval, Has 119% Upside According To This Analyst
La Jolla Meets ATHOS-3 Trial Endpoints, Dispels Market Controversy In The Process
Why Ionis Results Today Support A Pair Trade With Alnylam
AveXis Offers Easily The Best Treatment Option For SMA Type-1 Patients
Chardan Analyst Suggests An AveXis-Ionis Pair Trade
Here's What Makes La Jolla Pharma A 2017 Top Pick At Chardan
Catalyst Alert: Amgen/Regeneron Patent Case Appeal Could Be Decided By April
5 Key Takeaways In Regeneron's Praluent Suit, Steps Forward
The Medicines Co. Is A Top Pick For 2017
Why The Biogen-Ionis News Is A Boon For AveXis